Published by on September 7, 2021
Categories: Literature

Évaluation de l’imatinib dans la prise en charge de la leucémie myéloïde chronique au Gabon À propos de dix-sept cas Volume 26, numéro 2, Avril-Mai- Juin. REVUE MEDICALE DE LIEGE. Cliquer ICI pour déclencher le téléchargement de l’article. COMMENT JE TRAITE LA LEUCEMIE MYELOIDE CHRONIQUE. Résumé La leucémie myéloïde chronique (LMC) est un modèle de cancérogenèse. Son pronostic a été exceptionnellement amélioré grâce.

Author: Taushicage Vusar
Country: Belgium
Language: English (Spanish)
Genre: History
Published (Last): 2 May 2007
Pages: 303
PDF File Size: 4.20 Mb
ePub File Size: 2.48 Mb
ISBN: 583-8-30362-522-7
Downloads: 46350
Price: Free* [*Free Regsitration Required]
Uploader: Gushicage

Chronic myeloid leukaemia in South African blacks. Molecular biology of bcr-abl1-positive CML. Imatinib mesylate therapy in patients of chronic myeloid leukemia with Philadelphia chromosome positive: Tyrosine kinase inhibitor TKI therapy imatinib, dasatinib, nilotinib, bosutinib, ponatinib has led to improved overall and disease-free survival of patients.

Frequency of BCR-ABL fusion transcripts in Sudanese patients with chronic myeloid leukemia using real-time reverse transcription-polymerase chain reaction.

Chronic myeloid leukaemia at the Kenyatta National Hospital, Nairobi. The persistence of TKI-refractory leukemic stem cells could explain this result. Indian J Hematol Blood Transfus.

Chronic myeloid leukaemia in central Africans. The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties. Contact Help Who are we? If you want to subscribe to this journal, see our rates You can purchase this item in Pay Per View: Personal information regarding our website’s visitors, including their identity, is leucenie.


Top of the page – Article Outline. International recommendations facilitate the management of CML and treatment adjustments.

Outline Masquer le plan. You can move this window by clicking on the headline. Chronic myeloid leukemia advances in biology and new approaches to treatment.

Access to the full text of this leuceemie requires a subscription. Acellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. As per the Law relating to information storage and personal integrity, you have the right to oppose art 26 of that lawaccess art 34 of that law and rectify art 36 of that law your personal data.

East Afr Med J.

Leucémie myéloïde chronique (LMC)

Hematologic and cytogenetic response to Imatinib mesylate in chronic myelogenous leukemia. New strategies to eradicate these residual cells by targeting the hematopoietic niche or directly the leukemic stem cells are being developed. If lleucemie are a subscriber, please sign in ‘My Account’ at the top right of the screen.

N Engl J Med.

Leucémie myéloïde chronique

A retrospective study of leukemia epidemiology in Northern Tunisia. Analysis of the clinico-hematological relevance of the breakpoint location chroniqe M-BCR in chronic myeloid leukemia.

New technologies digital PCR, high-throughput sequencing or NGS were developed to improve the performances of existing methods. The Glivec international patient assistance programme: You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.


Journal page Archives Contents list.

Leucémie myéloïde chronique | Blausen Medical

Access to myeloid PDF text. Les inhibiteurs des kinases. Access to the text HTML. An experience from eastern India. S Af Med J. Clinical and pronognostic features of Nigerians with chronic myeloid leukemia.


For the remaining half of patients, the causes leading to the molecular relapse deserve to be further analyzed. Regional variations in age at diagnosis and overall survival among patients with myelpide myeloid leukemia from low and middle income countries. Finally, the immune system undoubtedly plays a crucial function in the control of residual leukemic cells; this role should be specified in the future. Clinical trials have validated TKI discontinuation strategies myeloidee patients with sustained deep molecular response.